News
Nerve growth factor therapy speeds gastric ulcer healing
Nerve growth factor therapy in aging rats improves angiogenesis and speeds gastric ulcer healing, which suggests possible applications in human...
News
Emicizumab beats factor VIII prophylaxis by a wide margin
In the HAVEN 3 trial, patients with hemophilia A without inhibitors had a significant reduction in bleeding events and no thrombotic events.
News
Capmatinib plus gefitinib overcomes EGFR resistance in NSCLC
In patients with a high level of MET amplification, responses were more common, with almost half of the NSCLC patients responding.
News
Rivaroxaban no help for heart failure outcomes
MUNICH - Rivaroxaban did not change outcome in patients with heart failure and coronary artery disease in the COMMANDER trial.
News
VTE risk unchanged by rivaroxaban after discharge
The MARINER study looked at postdischarge rivaroxaban in individuals who had been recently hospitalized and were at an increased risk of venous...
News
Hypofractionated radiation has untapped potential as RCC mets therapy
In a review of five studies of single-dose RT, 89% of patients achieved local control and less than 5% experienced severe toxicity.
News
Increasing incidence of metastatic RCC raises concerns for SREs
Investigators estimate that 85% of patients with metastatic RCC may experience SREs and related complications, with an average of more than two...
News
Nivolumab plus ipilimumab boosts response rate in refractory esophagogastric cancer
The nivolumab plus ipilimumab combination was considered most likely to offer clinical benefit for first-line metastatic esophagogastric cancer...
News
Vadastuximab talirine gives big boost to AML remission
Increased toxicity was a concern with the addition of the novel agent.
News
RA seroconversion not associated with sustained drug-free remission
Investigators looked at what achieving seronegativity in the first year of treatment meant for the chances of long-term sustained drug-free...
News
Third-line avelumab for gastric cancer safer than chemotherapy
Although no primary or secondary endpoints were met, avelumab demonstrated similar antitumor activity, compared with chemotherapy.
News
Rapid EGFR testing reduces time to therapy for patients with NSCLC
Rapid EGFR-specific testing in patients with NSCLC reduced median time to initiation (TTI) of therapy from 37 days to 22 days.
News
Prehospital plasma outperforms standard care
Providing thawed plasma on the way to the hospital helped reduce mortality for trauma patients.
News
Immunotherapies extend survival for melanoma patients with brain metastases
Patients with melanoma brain metastases receiving first-line checkpoint blockade immunotherapy had a 91% increase in 4-year survival.